ONConcept® announces the successful completion of a positive bioequivalence (BE) study in the European Union for Nilotinib. The study marks a significant milestone in our commitment to advancing pharmaceutical research and development in the field of Oncology.
The results demonstrate the efficacy of our formulation, covered by patent applications, and it allows us to file a dossier very soon with a potential launch in 2026.
This success reinforces our vision to providing timely and impactful solutions for patients globally, and it highlights ONConcept® commitment to improving patients’ health and positions us as a crucial provider for the future of oncology treatments.
The ONConcept® project built a basket of more than 20 products that provides a steady stream of new opportunities to our partners, with some of the molecules open to off-patent competition today and others having LoE dates for later in the decade.
ONConcept® is a Strategic Partnership between Bluepharma, Helm and Welding. An integrated European hub for delivering highly potent complex products in the oncology area, covering the entire value chain - from portfolio building to product development and market supply.